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DNA of Tuberculosis (TB) bacteria were found in mam-
moth bones and in Egyptian mummies and TB has 
affected mankind since its appearance, despite many 
efforts to control and eliminate it [1]. 
It was already well known since the sanatoria period 
(Germany, 1857) when treatment against TB consisted 
of good food, rest, sun, and fresh air that about half 
of TB cases recovered almost spontaneously. Robert 
Koch’s discovery of Mycobacterium tuberculosis in 
1882, Carlo Forlanini introduced the artificial pneumot-
horax in 1907 [1] and streptomycin was introduced at 
the end of the Second World War. These discoveries 
revolutionised the understanding and treatment of TB.
In spite of these discoveries, the epidemic trend has 
tended more towards an increase in recent years. The 
interventions recommended by the directly observed 
treatment, short-course (DOTS) and the Stop TB 
Strategy introduced in 2006 [2], e.g. rapid diagnosis 
of 70% of existing sputum smear-positive cases and 
effective treatment of 85% of them, are very power-
ful in reversing the epidemic trend. This was demon-
strated in several countries, e.g. in Peru and recently 
in Europe: Romania achieved 70/85% targets and, after 
an initial increase, was able to reduce both its case and 
case-fatality load [3].
Multidrug-resistant (MDR) and extensively drug-resist-
ant (XDR) TB mainly emerge as the result of misman-
agement of TB, either by the prescribing physician 
(regimen, dose, duration) or the patient (compliance). 
Failure of the programme contributes as well: poor 
quality drugs, lack of public health action in ensuring 
patient support and correcting early signs of sub-opti-
mal patient management represented by late sputum 
smear and culture conversion, presence of failures, 
defaulters and avoidable deaths.
As underlined by the joint ECDC and World Health 
Organization Regional Office for Europe TB report, 
launched on 18 March [11] the importance of good sur-
veillance to stem this trend cannot be underestimated. 
Where do we go with surveillance in Europe? Can we do 
more? How many MDR and XDR TB cases occur because 
of sub-optimal patient management?
This issue of Eurosurveillance casts light on these 
important questions with four interesting articles [4-7].
A paper by Manissero et al. from the ECDC reports on sur-
veillance data in twenty-two countries of the European 
Union (EU) and European Economic Area (EEA) done by 
the ECDC Tuberculosis Programme [4]. Treatment out-
come monitoring was performed on culture-confirmed 
pulmonary TB cases reported in 2007. While the overall 
treatment success rate was 73.8% (79.5% among new 
cases), only three countries achieved the 85% success 
rate target as a result of high defaulting and a relevant 
proportion of unknown outcomes.
A surveillance report by Devaux et al. [5] describes ret-
rospectively the results of second-line drug suscepti-
bility testing (DST) among MDR TB cases reported in 
20 countries of the WHO European Region (15 being 
EU countries) aimed at identifying XDR TB. In 18 coun-
tries (only) DST was performed for two or more of the 
second-line drugs defining XDR TB, with relevant inter-
country variation on the proportion of isolated tested. 
Overall, 10% of the MDR TB strains are found to be XDR.
A report by Ködmön et al. [6] describes the surveillance 
data collected by ECDC from EU and EEA countries. In 
2008, the combined proportion of new and retreated 
MDR TB cases was 6.0% of the total case load for the 25 
countries reporting data. Thirteen countries provided 
data on resistance to second-line drugs, allowing the 
identification of XDR TB cases. 68 XDR TB cases were 
reported in 2007 (6.1% of the MDR TB cases) and 90 in 
2008 (7.3% of the MDR TB cases). Latvia and Romania 
notified the highest number of XDR TB cases in 2008.
Next is a surveillance report by Caley et al. on a retro-
spective cohort study performed in the UK to quantify 
the risk of developing TB infection or disease following 
school contact with an infectious student. The report 
results suggest that greater levels of classroom 
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contact with a sputum smear positive student signifi-
cantly increases the risk of contracting both active TB 
disease and latent TB infection.
The results of the studies reported in this issue of 
Eurosurveillance allow us to point out some key topics:
•	  The completeness of reporting information (includ-
ing treatment outcomes), the proportion of cul-
ture-confirmed TB cases reported as well as the 
proportion of strains on which DST for both first- 
and second-line drugs is performed and reported 
are still sub-optimal overall in Europe. The rele-
vance of these pitfalls goes beyond the “simple” 
surveillance limitation, having the potential to 
affect other important TB control pillars, e.g. infec-
tion control and case-management. 
•	  MDR and XDR TB still persist in Europe. The high 
proportion of MDR TB identified among new TB 
cases reported by certain countries indicates that 
sub-optimal infection control practices are likely 
to occur, while the high percentage of MDR TB 
notified among retreatment cases is probably the 
result of sub-optimal case management in the past 
decade. 
ECDC is managing surveillance of TB at the EU level 
in collaboration with national correspondents, WHO 
Regional Office for Europe and partners. The joint 
ECDC and World Health Organization Regional Office 
for Europe TB report, launched on 18 March, shows 
that tuberculosis is still a matter of concern in Europe. 
Tuberculosis Surveillance in Europe 2008 presents the 
latest data on TB cases and shows that the decline in 
cases has slowed down [11]. 
With the enhanced and improved regular surveillance 
of anti-TB drugs and molecular surveillance of MDR TB 
cases, ECDC is offering an added value to the European 
surveillance [9,10]. Surveillance is an integral part of 
TB control, its contribution being essential to inform 
the programme on what is going on and what public 
health response is urgently needed. Investing in better 
“intelligence” is a pre-requisite to improve TB preven-
tion and control in Europe, in order to reach the elimi-
nation goal for Europe committed to in the early 1990s 
[8].
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